Amgen (AMGN) has seen a mixed landscape lately with a range of notable activity. The stock experienced a decline amid a market uptick, with stakeholders being eager to know how this will affect their investments. In the recent past, AMGN's share momentum cooled, triggering a sound valuation check.
Bank of America Securities continues to maintain a sell rating on AMGN while AMGN's stock started trading above the 50 and 200-day SMA. This recent development saw the company's shares surpass the 50 & 200-day moving averages. Major investment firms such as
Investment Research Partners LLC and
AIA Group Ltd recently invested significantly in AMGN, indicating a vote of confidence. On the flip side, Amgen stocks plummeted 2.36% due to sector rotation and regulatory rumors.
Amgen's dividend hikes and discounts under TrumpRx might alter the investment case for AMGN. It's also worth noting that the company's recent partnership with Ro on GLP-1 therapies looks to expand its Obesity strategy. In a major move, Amgen announced that it's investing over half a billion dollars in a new, state-of-the-art center for Science and Innovation. Despite some stock falls and turbulent market situations, AMGN continues to show strong Q4 financial results and improved investment outlook.
Amgen AMGN News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Thu, 19 Mar 2026 18:11:15 GMT -
Rating 5
- Innovation 7
- Information 6
- Rumor 2
